Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects
NCT02746237 is registered in ClinicalTrials.gov with Karos Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects
- Lead sponsor
- Karos Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2015
- Completion date
- August 31, 2016
- Enrollment
- 120 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.